Lucid Diagnostics Inc. Reports Q2 2025 Revenue of $1.2 Million, Processing 2,756 EsoGuard Tests
Reuters
Aug 13
<a href="https://laohu8.com/S/LUCD">Lucid Diagnostics</a> Inc. Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Revenue of $1.2 Million, Processing 2,756 EsoGuard Tests
Lucid Diagnostics Inc. has reported its financial results for the second quarter of 2025, ending June 30. The company processed 2,756 EsoGuard® tests in this period, generating revenue of $1.2 million. Lucid's cash and cash equivalents increased to $31.1 million as of June 30, 2025, from $22.4 million at the end of 2024, aided by a Confidentially Marketed Public Offering that resulted in net proceeds of approximately $16.1 million. The company ended the quarter with over $30 million in proforma cash, extending its financial runway beyond upcoming reimbursement milestones. Lucid has scheduled a Multi-Jurisdictional Contractor Advisory Committee meeting on September 4 to discuss the Medicare Local Coverage Determination for EsoGuard.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-011882), on August 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.